Biosimilar Denied: Hospira's Retacrit Could Head Back To FDA In First Half 2016
This article was originally published in The Pink Sheet Daily
Executive Summary
Breaking cone of silence around 351(k) applications with passed user fee dates, Hospira parent Pfizer says additional clinical trials not needed following complete response letter for epoetin alfa biosimilar.